- ISIN
- US12233L1070
- CUSIP
- 12233L107
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Jun 12, 2020
Highlights
- Market Cap
- $9.41M
- Enterprise Value
- -$49.09M
- EPS (TTM)
- -CN¥56.02
- Total Revenue (TTM)
- CN¥514.43M
- Gross Profit (TTM)
- CN¥383.52M
- EBITDA (TTM)
- -CN¥44.86M
- Year Range
- $5.96 - $41.72
- ROA (TTM)
- -7.53%
- ROE (TTM)
- -11.49%
- Avg. Volume (1M)
- 16K
- Avg. Volume Value (1M)
- $168.58K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BNR Performance Chart
Burning Rock Biotech Limited (BNR) is down 55.8% since the beginning of the year. At $9 per share, BNR is trading 78.7% below its 52-week high of $42. Investors who bought $1,000 worth of BNR shares 5 years ago would now be looking at an investment worth $39.
Loading charts...
Compare this symbol against anything
Returns By Period
Burning Rock Biotech Limited (BNR) has returned -55.83% so far this year and 56.97% over the past 12 months.
Burning Rock Biotech Limited
- 1D
- 0.56%
- 1M
- -9.37%
- 6M
- -73.87%
- YTD
- -55.83%
- 1Y
- 56.97%
- 3Y*
- -24.77%
- 5Y*
- -47.72%
- 10Y*
- —
- ALL TIME*
- -41.07%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
BNR Monthly Returns History
Based on dividend-adjusted daily data since Jun 12, 2020, BNR's average daily return is -0.03%, while the average monthly return is -0.45%.
Historically, 41% of months were positive and 59% were negative. The best month was Nov 2024 with a return of +119.2%, while the worst month was May 2022 at -56.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, BNR closed higher 45% of trading days. The best single day was Jul 23, 2025 with a return of +41.4%, while the worst single day was Mar 13, 2026 at -29.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 69.03% | -24.16% | -37.55% | 5.39% | -45.18% | -10.19% | 6.33% | -55.83% | |||||
| 2025 | -1.04% | -5.54% | -28.69% | -35.11% | 6.16% | 1.94% | 82.28% | 50.87% | -0.46% | 55.61% | 60.40% | -6.67% | 198.52% |
| 2024 | -7.53% | -0.90% | -14.57% | 3.71% | -5.31% | -9.83% | 14.16% | -28.06% | -38.34% | -13.94% | 119.22% | 9.58% | -27.42% |
| 2023 | 29.33% | 12.03% | -13.80% | 10.68% | -16.08% | -17.62% | -16.28% | -24.72% | -28.41% | -1.67% | -12.98% | 12.05% | -58.67% |
| 2022 | -5.56% | -6.33% | 10.20% | -40.69% | -56.44% | 21.25% | 9.62% | 22.88% | -39.03% | -13.81% | 21.84% | -10.36% | -76.39% |
| 2021 | 30.61% | 19.29% | -25.20% | 13.30% | -11.25% | 8.83% | -22.67% | -18.22% | -4.03% | -21.20% | 9.72% | -38.36% | -58.74% |
Benchmark Metrics
Burning Rock Biotech Limited has an annualized alpha of -22.42%, beta of 1.04, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 12, 2020.
- This stock participated in 193.13% of S&P 500 Index downside but only -29.20% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -22.42%
- Beta
- 1.04
- R²
- 0.03
- Upside Capture
- -29.20%
- Downside Capture
- 193.13%
Return for Risk
Risk / Return Rank
BNR ranks 64 for risk / return — above 64% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Burning Rock Biotech Limited (BNR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BNR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.98 | ||
| Sortino ratioReturn per unit of downside risk | -0.41 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.25 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | 0.66 | 2.00 | -1.34 |
| Martin ratioReturn relative to average drawdown | 1.23 | 8.49 | -7.26 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Burning Rock Biotech Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Burning Rock Biotech Limited was 99.41%, occurring on May 7, 2025. The portfolio has not yet recovered.
The current Burning Rock Biotech Limited drawdown is 97.75%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.41%May 2025 | 4y 2mo | — | 5y 5moFeb 2021 - now | 2025 selloff2025 |
-39.33%Sep 2020 | 2mo 17d | 4mo 8d | 6mo 25dJun 2020 - Jan 2021 | — |
-25.28%Jan 2021 | 5d | 26d | 1mo 1dJan 2021 - Feb 2021 | — |
-5.77%Jun 2020 | 1d | 3d | 3dJun 2020 - Jun 2020 | — |
-1.38%Jan 2021 | 1d | 1d | 1dJan 2021 - Jan 2021 | — |
Drawdown Indicators
| BNR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.41% | -56.78% | -42.63% |
Max Drawdown (1Y)Largest decline over 1 year | -82.85% | -9.10% | -73.75% |
Max Drawdown (3Y)Largest decline over 3 years | -87.32% | -18.90% | -68.42% |
Max Drawdown (5Y)Largest decline over 5 years | -99.04% | -25.43% | -73.61% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.75% | -1.58% | -96.17% |
Average DrawdownAverage peak-to-trough decline | -78.67% | -10.70% | -67.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.34% | 2.14% | +42.20% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Burning Rock Biotech Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Burning Rock Biotech Limited is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BNR relative to other companies in the Diagnostics & Research industry. Currently, BNR has a P/S ratio of 0.1. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BNR in comparison with other companies in the Diagnostics & Research industry. Currently, BNR has a P/B value of 0.1. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BNR
Add Burning Rock Biotech Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BNR